Profile data is unavailable for this security.
About the company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
- Revenue in USD (TTM)2.36m
- Net income in USD-65.53m
- Incorporated2016
- Employees73.00
- LocationXilio Therapeutics Inc828 Winter Street, Suite 300WALTHAM 02451United StatesUSA
- Phone+1 (617) 430-4680
- Fax+1 (302) 655-5049
- Websitehttps://xiliotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| vTv Therapeutics Inc | 1.00m | -20.18m | 40.64m | 16.00 | -- | 2.47 | -- | 40.64 | -6.81 | -6.81 | 0.2701 | 5.47 | 0.029 | -- | 6.54 | 62,500.00 | -73.77 | -111.84 | -170.69 | -- | -- | -- | -2,540.90 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| DURECT Corp | 8.41m | -15.80m | 41.28m | 47.00 | -- | 8.20 | -- | 4.91 | -0.5283 | -0.5283 | 0.2842 | 0.1623 | 0.2143 | 0.682 | 7.26 | 145,017.20 | -40.25 | -37.34 | -208.53 | -53.44 | 80.80 | 91.83 | -187.84 | -139.11 | 0.797 | -38.83 | 0.7135 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Lantern Pharma Inc | 0.00 | -17.75m | 41.34m | 21.00 | -- | 1.34 | -- | -- | -1.65 | -1.65 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -40.79 | -28.83 | -44.71 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| Rallybio Corp | 299.00k | -73.88m | 41.49m | 43.00 | -- | 0.5185 | -- | 138.75 | -1.79 | -1.79 | 0.0072 | 1.93 | 0.0025 | -- | -- | 6,953.49 | -61.57 | -- | -67.23 | -- | -- | -- | -24,709.37 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Carisma Therapeutics Inc | 20.71m | -72.50m | 41.96m | 107.00 | -- | 116.56 | -- | 2.03 | -1.78 | -1.78 | 0.5075 | 0.0087 | 0.2153 | -- | -- | 193,551.40 | -75.38 | -30.87 | -91.33 | -34.47 | -- | -- | -350.08 | -255.66 | -- | -- | 0.8322 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -8.20m | 42.27m | 2.00 | -- | 11.09 | -- | -- | -0.318 | -0.318 | 0.00 | 0.147 | 0.00 | -- | -- | 0.00 | -104.19 | -- | -113.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| Clene Inc. | 442.00k | -30.46m | 43.14m | 82.00 | -- | -- | -- | 97.61 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Xilio Therapeutics Inc | 2.36m | -65.53m | 43.52m | 73.00 | -- | 1.30 | -- | 18.46 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Hookipa Pharma Inc | 52.16m | -48.60m | 45.33m | 151.00 | -- | 0.5266 | -- | 0.8689 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 45.35m | 4.00 | -- | -- | -- | 66.31 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.08m | 45.45m | 5.00 | -- | 8.47 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Vyne Therapeutics Inc | 486.00k | -27.86m | 46.61m | 10.00 | -- | 0.6135 | -- | 95.90 | -2.41 | -2.57 | 0.0162 | 5.15 | 0.0087 | -- | -- | 48,600.00 | -49.92 | -108.41 | -59.60 | -138.57 | -- | -- | -5,732.31 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -12.59m | 46.74m | 14.00 | -- | 2.70 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Data as of Nov 08 2024. Currency figures normalised to Xilio Therapeutics Inc's reporting currency: US Dollar USD
14.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rock Springs Capital Management LPas of 30 Jun 2024 | 3.00m | 6.83% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 1.11m | 2.53% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 899.59k | 2.05% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 295.00k | 0.67% |
| Balyasny Asset Management LPas of 30 Jun 2024 | 272.49k | 0.62% |
| FIL Investment Advisors (UK) Ltd.as of 30 Jun 2024 | 218.71k | 0.50% |
| Geode Capital Management LLCas of 30 Jun 2024 | 182.86k | 0.42% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 71.08k | 0.16% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 60.74k | 0.14% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 43.39k | 0.10% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
